Beyond the Statin: What IMPROVE-IT and FOURIER Prove About Lowering LDL Further

Two large trials answer the same question. IMPROVE-IT showed that adding ezetimibe to a statin lowered LDL cholesterol modestly and cut cardiovascular events by a small but statistically real margin. FOURIER showed that the PCSK9 inhibitor evolocumab drove LDL far lower and reduced major events by about 15 percent. Together they support a simple principle: lower the LDL, and you tend to see fewer events, with the size of the benefit tracking the size of the LDL drop.

Why these two trials matter

For decades, statins were the only drug class with strong outcomes evidence for lowering LDL cholesterol. That left an open question with real stakes. If you add a second agent that lowers LDL through a different mechanism, do patients actually have fewer heart attacks and strokes, or does the extra LDL reduction fail to translate into fewer events? A lower number on a lab report is not the same as a longer, healthier life. IMPROVE-IT and FOURIER were designed to test whether the benefit is real when you go below what a statin alone achieves.

IMPROVE-IT: a modest drug, a modest but real effect

IMPROVE-IT, published in the New England Journal of Medicine in 2015, enrolled 18,144 patients who had been hospitalized for an acute coronary syndrome within the prior 10 days. Everyone received simvastatin. Half were also given ezetimibe, which blocks cholesterol absorption in the gut, and half received placebo on top of the statin.

The LDL separation was modest. The time-weighted average LDL was about 54 mg/dL in the ezetimibe group versus about 70 mg/dL in the statin-only group, a difference of roughly 16 mg/dL. Over a median follow-up of about six years, the primary composite endpoint of cardiovascular death, major coronary events, and stroke occurred in 32.7 percent of the ezetimibe group versus 34.7 percent of the statin-only group. That is an absolute difference of about 2 percentage points, a hazard ratio of 0.936, and a p-value of 0.016.

Two things about that result deserve emphasis. First, the effect is genuinely small. You would need to treat many patients for years to prevent one event, and the confidence interval sits close to the line of no benefit. Second, and more importantly for the field, IMPROVE-IT was the first major trial to show that a non-statin LDL-lowering drug added to a statin reduces cardiovascular events. It supplied direct evidence that the benefit comes from lowering LDL itself, not from some statin-specific property. A modest LDL reduction bought a modest event reduction, in proportion.

FOURIER: a bigger LDL drop, a bigger effect

FOURIER, published in the same journal in 2017, tested a far more potent tool. It enrolled 27,564 patients with established atherosclerotic cardiovascular disease and LDL of 70 mg/dL or higher despite statin therapy. On top of their statin, patients received either evolocumab, an injectable monoclonal antibody that inhibits PCSK9 and sharply increases the liver's clearance of LDL, or placebo.

The LDL change was dramatic. Evolocumab lowered LDL by about 59 percent, from a median of roughly 92 mg/dL to about 30 mg/dL, a level far below what statins alone reach. Over a median follow-up of about 2.2 years, the primary composite endpoint fell with a hazard ratio of 0.85, a 15 percent relative reduction. The key secondary endpoint of cardiovascular death, heart attack, or stroke fell further, with a hazard ratio of 0.80.

There is an important caveat. FOURIER did not show a reduction in cardiovascular death or in death from any cause over its follow-up. The benefit was driven by fewer heart attacks, strokes, and revascularizations. The trial also did not find an increase in new-onset diabetes or neurocognitive events over its duration, addressing two safety concerns raised about very low LDL levels, though the follow-up was relatively short for questions that play out over decades.

Reading the two trials together

Placed side by side, the trials tell a coherent story. Ezetimibe produced a small LDL drop and a small event reduction. Evolocumab produced a large LDL drop and a larger event reduction. The relationship between how far LDL falls and how much risk falls is roughly linear, and it holds well below the levels statins alone achieve. This is the strongest practical support for the idea that LDL is causal in atherosclerosis, not merely correlated with it.

Several qualifiers keep this from being a blanket endorsement of aggressive add-on therapy for everyone. Both trials studied high-risk patients: recent acute coronary syndrome in IMPROVE-IT, established vascular disease in FOURIER. The results do not automatically extend to lower-risk primary prevention, where the absolute benefit would be smaller. Relative risk reductions can sound impressive while the absolute benefit for any one person remains modest, especially over a few years. And neither add-on reduced mortality in its trial window. The value of these drugs is best understood as preventing nonfatal events in people whose baseline risk is already high, where a 15 to 20 percent relative reduction translates into a meaningful number of avoided heart attacks and strokes.

Cost, the burden of an injectable versus a pill, and individual risk all factor into whether intensifying LDL-lowering makes sense for a given person. Those are decisions to work through with a treating clinician who knows the full clinical picture. This article is educational and is not medical advice.

What the evidence establishes is narrower and firmer than marketing around any single product. Lowering LDL further, on top of a statin, reduces cardiovascular events in high-risk patients, and the magnitude of that benefit scales with the magnitude of the LDL reduction. IMPROVE-IT proved the principle with a small effect; FOURIER confirmed it with a larger one.